Pancreatic Cancer Treatment: BET Inhibitors & HDACs

Authors and Affiliations:

• Pawel K. Mazur^1,2, Timo Kuschma^1,2, Leanne C. ‍Sayles¹, E. Alejandro Sweet-Cordero¹,⁢ Julien Sage^1,2
• Alexander Herner³, Matthias⁢ Wirth³, Marija Trajkovic-Arsic³, Aayush ⁢Gupta³, Roland M. Schmid³, Guenter Schneider³, Jens T. Siveke³
• Stephano ‍S. Mello^2,4, Laura ‍D. ‍Attardi^2,4
• Simone Hausmann⁵, Mert Erkan⁵, Jörg Kleeff⁵
• Irene Esposito⁶

¹Department ⁤of Pediatrics, Stanford university School of Medicine, California, USA

²Department of Genetics, Stanford University school of Medicine, California, USA

³Second Department of Internal Medicine, Klinikum rechts der Isar, Technische ⁣Universität München, Munich, Germany

⁴Department of Radiation Oncology, Stanford University School of Medicine, California, USA

⁵Department of Surgery, Klinikum rechts der Isar, Technische universität München, Munich, Germany

⁶Institute of Pathology, Heinrich-Heine university, Düsseldorf, Germany

⁷Division of Translational Solid Tumor oncology, German Cancer Consortium⁤ (DKTK), partner site Essen and German Cancer Research Center (DKFZ), Heidelberg,⁤ Germany

These authors contributed equally:‍ Pawel K. Mazur, Alexander ⁣Herner.

Present Addresses:

• Mert Erkan, Department of Surgery, Koc University ‍School of Medicine, Istanbul, Turkey
• Irene Esposito, Institute‍ of Pathology, heinrich-Heine University, Düsseldorf, Germany
• Jens T.Siveke, Division ‍of Translational solid Tumor Oncology, German Cancer Consortium (DKTK), partner site Essen and German⁢ Cancer Research Center (DKFZ), Heidelberg, Germany